Abstract

1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).

Links

Publisher Full Text

Authors

Jaume M, Yip MS, Kam YW, Cheung CY, Kien F, Roberts A, Li PH, Dutry I, Escriou N, Daeron M, Bruzzone R, Subbarao K, Peiris JS, Nal B, Altmeyer R

Institution

HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China. breizh@hku.hk

Source

Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 18 Suppl 2: 2012 Feb pg 31-6

MeSH

Animals
Antibodies, Neutralizing
Antibodies, Viral
Antibody-Dependent Enhancement
Cell Line, Tumor
Cysteine Proteases
Humans
Hydrogen-Ion Concentration
Membrane Glycoproteins
Mice
Mice, Inbred BALB C
Monocytes
Peptidyl-Dipeptidase A
Receptors, Fc
SARS Virus
Severe Acute Respiratory Syndrome
Vaccines
Viral Envelope Proteins
Virus Internalization

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22311359